ArticleMMWR. Morbidity and mortality weekly report2023
Progress Toward Measles Elimination - Worldwide, 2000-2022.
Article in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.
- Uptake of the Second Dose of the Measles Vaccine and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2025Pooled it
- Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial.Frontiers in immunology · 2025Trial
- Measles incidence and measles-containing vaccine coverage in Chereponi District, Ghana, 2019-2024: A retrospective analysis of routine surveillance and immunization data.Global epidemiology · 2026Article
- Measles disease outbreaks are surging again globally in 2026.Virulence · 2026Article
- Evaluation of the measles surveillance system in Chereponi District, Ghana, 2019-2024.Public health in practice (Oxford, England) · 2026Article
- Reasons for Childhood Vaccine Refusal: A Cross-Sectional Study in South-Eastern Türkiye.Children (Basel, Switzerland) · 2026Article
- Measles and Rubella Immunity Profile of Healthcare Workers in Bulgaria: A Cross-Sectional Study.Vaccines · 2026Article
- Analysis of measles outbreaks reported to Integrated Disease Surveillance Programme (IDSP), India, 2019-2023.BMC infectious diseases · 2026Article
- Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024.Open forum infectious diseases · 2026Article
- Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).Vaccines · 2026Article
- Article
- Association between ambient temperature and childhood vaccination coverage in low- and middle-income countries.BMC medicine · 2026Article
- Measles-rubella surveillance and its facilitators and barriers in Bagmati province, Nepal: a mixed methods study.BMC infectious diseases · 2026Article
- Optional Vaccines, Collective Risk.Cureus · 2026Article
- The global threat of vaccine-preventable neurological diseases.Nature reviews. Neurology · 2026Review
- Waning of vaccine-induced measles antibodies and population immunity gaps in the post-elimination era: a multicenter seroepidemiological study in China.Frontiers in immunology · 2026Article
- Factors associated with laboratory-confirmed measles cases during the 2023 and 2024 outbreaks in Tanzania-a mixed-methods study.Frontiers in public health · 2026Article
- Article
- Article
- Timeliness and Equity: An Analysis of Measles Herd Immunity in a Regional Area of Australia.Vaccines · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed to eliminating measles; however, no region has achieved and sustained measles elimination. This report describes measles elimination progress during 2000-2022. During 2000-2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% to 86%, then declined to 81% in 2021 during the COVID-19 pandemic, representing the lowest coverage since 2008. In 2022, first-dose MCV coverage increased to 83%. Only one half (72) of 144 countries reporting measles cases achieved the measles surveillance indicator target of two or more discarded cases per 100,000 population in 2022. During 2021-2022, estimated measles cases increased 18%, from 7,802,000 to 9,232,300, and the number of countries experiencing large or disruptive outbreaks increased from 22 to 37. Estimated measles deaths increased 43% during 2021-2022, from 95,000 to 136,200. Nonetheless, an estimated 57 million measles deaths were averted by vaccination during 2000-2022. In 2022, measles vaccination coverage and global surveillance showed some recovery from the COVID-19 pandemic setbacks; however, coverage declined in low-income countries, and globally, years of suboptimal immunization coverage left millions of children unprotected. Urgent reversal of coverage setbacks experienced during the COVID-19 pandemic can be accomplished by renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.